VX1 Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VX1 from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$377.80 |
52 Week High | US$420.95 |
52 Week Low | US$291.95 |
Beta | 0.37 |
1 Month Change | -1.96% |
3 Month Change | -4.93% |
1 Year Change | 25.77% |
3 Year Change | 113.74% |
5 Year Change | 148.81% |
Change since IPO | 1,251.70% |
Recent News & Updates
Recent updates
Shareholder Returns
VX1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 1.9% | -1.2% | 1.7% |
1Y | 25.8% | -23.0% | 2.3% |
Return vs Industry: VX1 exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: VX1 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
VX1 volatility | |
---|---|
VX1 Average Weekly Movement | 2.6% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: VX1's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
VX1 fundamental statistics | |
---|---|
Market cap | €97.79b |
Earnings (TTM) | €3.38b |
Revenue (TTM) | €9.22b |
28.6x
P/E Ratio10.5x
P/S RatioIs VX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VX1 income statement (TTM) | |
---|---|
Revenue | US$9.87b |
Cost of Revenue | US$4.43b |
Gross Profit | US$5.44b |
Other Expenses | US$1.82b |
Earnings | US$3.62b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
Earnings per share (EPS) | 14.00 |
Gross Margin | 55.16% |
Net Profit Margin | 36.68% |
Debt/Equity Ratio | 0% |
How did VX1 perform over the long term?
See historical performance and comparison